Drugs firm using artificial intelligence to find new treatments
C4X Discovery Holdings, the Manchester-based drugs discovery firm, has announced a partnership deal with state-of-the-art artificial intelligence firm GTN.
It says the partnership will maximise insights from shape-based chemistry and generate novel drug candidates in neurodegeneration, the progressive loss of structure or function of neurons which is associated with conditions such as Parkinson's disease, Alzheimer's disease, and Huntington's disease.
London-based GTN is a 'disruptive' new player in the field of drug discovery a... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...